Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.58 |
| ▸ | HTR3A | P46098 | 1/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5832115 | 0.95 | CHRNA7 (0.55) | CHRNA7HTR3ACHRNB4CHRNA3KDM4E | |
| SCHEMBL928191 | 0.92 | CHRNA7 (0.68) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL2676639 | 0.86 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL1449402 | 0.86 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL1794434 | 0.80 | CHRNA7 (0.50) | CHRNA7HTR3ACHRNB4CHRNA3NPC1 | |
| SCHEMBL3390808 | 0.78 | CHRNA7 (0.50) | CHRNA7HTR3ACHRNB4CHRNA3MAPT | |
| SCHEMBL3394101 | 0.78 | SCD (0.50) | CHRNA7HTR3ACHRNB4CHRNA3SCD | |
| SCHEMBL928032 | 0.78 | CHRNA7 (0.60) | CHRNA7HTR3ACHRNB4CHRNA3KDM4E | |
| SCHEMBL3389698 | 0.78 | CHRNA7 (0.52) | CHRNA7HTR3ACHRNB4CHRNA3SCD | |
| SCHEMBL3549325 | 0.78 | CHRNB2 (0.35) | CHRNB4CHRNA3MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | claimed |
| CN-1440411-A | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | CN | claimed |
| EP-1301514-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-04-16 | — | — | EP | claimed |
| WO-2002002564-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-10 | — | — | WO | claimed |
| US-7060699-B2 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2006-06-13 | — | — | US | disclosed |
| EP-1301514-B1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2005-01-26 | — | — | EP | disclosed |
| CN-1185233-C | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2005-01-19 | — | — | CN | disclosed |
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| CN-1440411-A | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | CN | disclosed |
| EP-1301514-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002002564-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885HTR3A 59/4885CHRNB4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.